Developing TB Vaccines for People with HIV: consensus statements from an international expert panel

• Type of Material: Article
• Authors: Maurine D. Miner, Fred Hutchinson Cancer Research Center; Mark Hatherill, University of Cape Town; Vidya Mave, Johns Hopkins University; Glenda E. Gray, South African Medical Research Council; Sharon Nachman, Stony Brook University; Sarah W. Read, National Institutes of Health; Richard G. White, The London School of Hygiene and Tropical Medicine; Anneke Hessling, Desmond Tutu TB Centre; Frank Cobelens, Amsterdam University; Sheral Patel, US Food and Drug Administration; Mike Frick, Treatment Action Group; Theodore Bailey, Greater Baltimore Medical Center; Robert Seder, National Institutes of Health; Joanne Flynn, University of Pittsburgh; Jyothi Rengarajan, Emory University; Deepak Kaushal, Texas Biomedical Research Institute; Willem Hanekom, Africa Health Research Institute; Alexander C. Schmidt, Gates Medical Research Institute; Thomas Scriba, University of Cape Town; Elisa Nemes, University of Cape Town; Erica Andersen-Nissen, Fred Hutchinson Cancer Research Center; Alan Landay, Rush Medical Center; Susan E. Dorman, University of South Carolina, Charleston; Grace Aldrovandi, University of California, Los Angeles; Lisa Marie Cranmer, Emory University; Cheryl Liane Day, Emory University; Alberto L. Garcia-Basteiro, Universitat de Barcelona; Andrew Fiore-Gartland, Fred Hutchinson Cancer Research Center; Robin Mogg, Takeda Pharmaceutical Company Limited; James G. Kublin, Fred Hutchinson Cancer Research Center; Amita Gupta, Johns Hopkins University; Gavin Churchyard, Vanderbilt University
• Language: English
• Date: 2022-10-11
• Publisher: Elsevier
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2022 Elsevier Ltd. All rights reserved.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): https://doi.org/10.1016/S2352-3018(22)00255-7
• Title of Journal or Parent Work: The Lancet HIV
• Volume: 9
• Issue: 11
• Start Page: e791
• End Page: e800
• Grant/Funding Information: Funding was provided by NIH grants UM1 AI 068636, UM1 AI068614, 5UM1AI154463, UM1 AI 068636 (GC); UM1 AI068614-14 (JK); NIH UM1 AI069465 (AG).
• Keywords: HIV; Mycobacterium tuberculosis; tuberculosis
• Research Categories: Biology, Virology; Health Sciences, Public Health; Health Sciences, Immunology

Abstract

New tuberculosis (TB) vaccine candidates in the development pipeline need to be studied in people with HIV, who are at high risk of developing Mycobacterium tuberculosis (Mtb) infection and TB disease and tend to develop less robust vaccine induced immune responses. Many questions in the development of a TB vaccine for people with HIV remain unanswered. To address the gaps in developing TB vaccines for people with HIV, a series of symposia was held that posed framing questions to a panel of international experts. Framing questions specific to developing TB vaccines for people with HIV included: 1) What is the use case or rationale for developing TB vaccines? 2) What is the landscape of TB vaccines? 3) Which vaccine candidates should be prioritized? 4) What are the TB vaccine trial design considerations? 5) What is the role of immunological correlates of protection? and 6) What are the gaps in preclinical models for studying TB vaccines? The international expert panel formulated consensus statements to each of the framing questions, with the intention of informing TB vaccine development and the prioritization of clinical trials for inclusion of people with HIV.